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ABSTRACT
Thiosemicarbazones are chelators of transition metals such as iron or copper 
whose anticancer potency is intensively investigated. Although two compounds 
from this class have entered clinical trials, their precise mechanism of action is still 
unknown. Recent studies have suggested the mobilization of the iron ions from a cell, 
as well as the inhibition of ribonucleotide reductase, and the formation of reactive 
oxygen species. The complexity and vague nature of this mechanism not only impedes 
a more rational design of novel compounds, but also the further development of those 
that are highly active that are already in the preclinical phase. In the current work, 
a series of highly active thiosemicarbazones was studied for their antiproliferative 
activity in vitro. Our experiments indicate that these complexes have ionophoric 
properties and redox activity. They appeared to be very effective generating reactive 
oxygen species and deregulating the antioxidative potential of a cell. Moreover, the 
genes that are responsible for antioxidant capacity were considerably deregulated, 
which led to the induction of apoptosis and cell cycle arrest. On the other hand, good 
intercalating properties of the studied compounds may explain their ability to cleave 
DNA strands and to also poison related enzymes through the formation of reactive 
oxygen species. These findings may help to explain the particularly high selectivity 
that they have over normal cells, which generally have a stronger redox equilibrium. 
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INTRODUCTION
The disruption of the cellular redox homeostasis 
of tumor cells appears to be an attractive and promising 
approach for cancer therapy. Cancer cells have increased 
reactive oxygen species (ROS) levels compared to normal 
cells. This phenomenon is associated with oncogenic 
transformations and glycolytic metabolic adaptations, 
which leads to the acceleration of metabolism [1]. 
Thus, the high level of ROS in tumor cells renders them 
more susceptible to the harmful effects of the increased 
oxidative stress that is induced by treatment with drugs. 
The aforementioned effects promote the generation of 
ROS and/or debilitates the antioxidant system defenses 
in a cell [2]. This approach may be an effective strategy 
to eliminate abnormal cells, including colon, pancreatic, 
prostate and breast cancers, which are characterized by 
elevated basal ROS levels [3, 4]. Importantly, in cancer 
cells, the overexpression of P-glycoprotein and the 
phenomenon of multi-drug resistance (MDR) is associated 
with an elevated level of ROS and a modified antioxidative 
capacity [5]. In particular, a high level of many antioxidant 
proteins plays a pivotal role in the development of multi-
drug resistance [6].
The overproduction of ROS may affect the 
regulation of the expression of certain genes and proteins 
that are responsible for restoring the redox balance. 
Among them, the most important genes are those 
encoding manganese superoxide dismutase (MnSOD) 
and catalase (CAT). MnSOD is a mitochondrial protein 
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that is extremely efficient in scavenging superoxide 
anions by converting them into hydrogen peroxide, 
which is further eliminated by CAT in cytosol [7, 8]. In 
addition, glutathione (GSH), which is the most important 
intracellular non-enzymatic antioxidant, plays a central 
role in the antioxidant system of a cell. Moreover, GSH 
also plays an essential role in maintaining the balance of 
NAD+/NADH, NADP+/NADPH and GSH/GSSG, which 
characterize the cellular redox state [9]. Deregulation of 
the endogenous antioxidant systems, including enzymes 
(e.g. MnSOD and CAT) and non-enzymatic antioxidant 
(e.g. GSH), causes many alterations that lead to the 
induction of oxidative stress. Elevated oxidative stress 
results in the oxidation of the reduced form of GSH 
into glutathione disulfide (GSSG) or its conjugation 
with endogenous and exogenous electrophiles or efflux 
of glutathione from the cells. All of these mechanisms 
lead to an overall depletion of GSH and thus result in 
mitochondrial dysfunction [10–12]. Generally, oxidative 
stress can result in detrimental cellular damage including 
lipid peroxidation, DNA adduct formation, protein 
oxidation and enzyme inactivation, which in turn can lead 
to cell death through cell cycle arrest or the activation of 
certain transcription factors [13]. 
Iron and copper play a crucial role in regulating 
many redox processes that are essential for cell 
homeostasis [14]. Iron is important for cellular respiration, 
oxygen transport, ATP generation, the synthesis of heme 
and DNA [15]. Similarly, copper is responsible for enzyme 
activity, oxygen transport and cell signaling. Those 
elements, due to their low electron transfer energy, are co-
factors for many redox enzymes [16, 17]. This explains 
the higher requirement for these essential metals that is 
observed in rapidly growing and proliferating neoplastic 
cells. Organic compounds that chelate the metal ions 
are able to alter the metabolism and cellular signaling 
pathways, which may be considered to be an attractive 
approach in cancer treatment. 
The deprivation of iron through chelation leads to 
the activation of various cytotoxic mechanisms in a cell 
[18, 19]. Thiosemicarbazones (TSC) are a well-known 
class of compounds with extremely potent antitumor 
properties, which are associated with their ability to chelate 
metal ions [20–23]. The exact molecular mechanism of 
action of TSC is still insufficiently clear. Many reports 
have indicated that a multifaceted mechanism of action 
is possible for this class of compounds [23–26]. Namely, 
TSC may affect the cell cycle progression by trapping 
Fe and depleting the iron pool in cells, which leads to 
cell cycle arrest in the G1/S phase and the inhibition of 
ribonucleotide reductase (RR), which is an enzyme that is 
necessary in DNA synthesis [27, 28]. Other studies have 
demonstrated that TSC can trigger apoptosis through the 
up-regulation of the metastasis suppressor protein, N-myc 
Downstream Regulated Gene 1 (Ndrg1) [29]. Furthermore, 
Ndrg1 expression is induced in response to various forms 
of cellular stress [30], which may be associated with 
the formation of redox-active metal complexes. Such 
complexes are known to produce reactive oxygen species 
via the Fenton reaction [23]. The latter mechanism is 
especially significant due to the emerging new targets 
in anticancer oxidative therapy, as well as its ability to 
increase the selective of activity of iron chelators against 
cancer cells [20, 23]. 
Currently, this class of compounds is being 
extensively investigated in clinical trials. In fact, the 
first inhibitor of RR–Triapine has completed phase II, 
while DpC has recently entered phase I of clinical trials 
(NCT02688101) [31, 32]. Among the most active TSC 
are compounds that are based on the dipyridylketone 
scaffold such as DpC, which is an analog of a first-
generation compound – Dp44mT (Figure 1). Although both 
compounds have exhibited a potent and selective activity 
against a variety of aggressive solid tumors in vitro and in 
vivo, DpC has also demonstrated a high tolerability in vivo 
[23, 29, 33].
The broad investigation of TSC has led to even 
more active compounds with a high selectivity [34, 35]. 
Moreover, we reported that the relationship between the 
structure and activity of these compounds, in particular 
the presence of soft donor atoms, plays a key role in the 
formation of redox active iron complexes [35]. More 
recently, other TSC derivatives have been applied as 
enhancers in photodynamic therapy (PDT) [36, 37]. 
Moreover, it has been reported that combining the copper 
complexes of TSC with azines eliminates cancer cells by 
inducing oxidative stress [38]. 
Although continuous efforts have allowed many 
aspects of the mechanisms of the activity of TSC to be 
clarified, other questions have been raised as the activity of 
the metals appears to be more complex. Iron mobilization 
from cytosol has also been observed to prevent the uptake 
of Fe from transferrin for active compounds [39]. On 
the other hand, it has been reported that Dp44mT and 
their complexes with iron and copper cause apoptosis by 
generating cytotoxic ROS [23, 40]. Moreover, Akladios 
et al. reported that in some TSC, the addition of metal 
cations may increase activity [41, 42]. This observation 
led to the alternative use of TSC as ionophores. In fact, the 
structure of the metal-TSC complexes seems to be crucial 
for the overall ability to chelate ions as has been revealed 
in Triapine [43]. Thus, more comprehensive investigations 
are necessary to fully understand the complex molecular 
mechanism of action of TSC chelators [44].
In the current study, we explored the redox potency 
and mechanism of action of novel TSC presented in Figure 
1. We selected a series of the most effective anticancer 
TSC that are based on dipyridylketone and quinoline 
from among those that have been described recently 
[35, 36]. Moreover, their newly synthesized analogs and 
doxorubicin (DOX) were used as control. For the in vitro 
cytotoxicity tests, we used a colon carcinoma (HCT116) 
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and a breast cancer (MCF-7) cell lines with normal 
human fibroblasts (NHDF) as the non-malignant control. 
In addition to the normal toxicity assays with iron and 
copper ions, the redox state in the cells was investigated. 
Finally, the impact of any impaired antioxidant potential 




All of the structures of the investigated 
thiosemicarbazone derivatives that contain the quinoline, 
8-hydroxyquinoline, and di-2-pyridylketone moieties are 
presented in Figure 1. The compounds used in this study 
were selected based on their ability of inhibit the growth 
of HCT116 p53+/+ cells in sub-nanomolar concentrations. 
Furthermore, we synthesized two novel TSC analogs – 1b 
and 1c.
Synthesis
The heteroaromatic TSC analogs were synthesized 
by reacting the respective heteroaromatic ketone or 
carbaldehyde and thiosemicarbazide under microwave 
irradiation. We applied here highly efficient microwave-
assisted methodology, which was previously described 
by our group [35]. In general, the use of microwaves 
improved the purity of final compounds, providing the 
high assays of TSC without flash chromatography. 
Cytotoxicity studies
The antiproliferative activities of all of the tested 
compounds against HCT116 and MCF-7 cells are 
presented in Table 1 as IC50 along with experiments with 
the increased metal ion concentrations. 
Compound 3a was the most potent subnanomolar 
inhibitor in the colon cancer line followed by 3b and 2a, 
that were roughly as active as Dp44mT. However, 3a was 
also the most toxic against normal fibroblasts (NHDF). In 
terms of selectivity, compounds 1a, 2a and 2b appeared 
to be the most useful with 2a having a selectivity index 
(for HCT116) equal to 2.8·103 (Supplementary Table 
1). Interestingly, all of the compounds that were tested 
showed various patterns of activity against the MCF-7 
cell line. 3b was the most active while 1c had the highest 
selectivity (1.0·103 - for MCF-7). 
The influence of iron on the toxicity of TSC is 
particularly interesting. We found that the addition of 
Fe2+ ions completely eliminated the activity of all of the 
compounds that were tested within the concentration 
levels (data not presented). On the other hand, in the 
presence of Fe3+, the TSC retained their activity against 
HCT116 and MCF-7 cells. At first glance, these results 
may seem in contrast to the literature data where 
Triapine and its derivatives were considerably less active 
when administered with Fe3+ [43]. This, however, may 
suggest how important the basal level of iron and ROS 
in cancerous cells is. We also examined the influence 
of copper ions on the cytotoxic effects that are induced 
by TSC in HCT116 and MCF-7 cells. As expected, we 
Figure 1: Structures of the studied compounds.
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observed that supplementation with this redox-active metal 
caused a significant increase in the cytotoxicity of the TSC. 
In general, we did not observe any uniform patterns of 
improved cytotoxicity with copper for the tested TSC in 
the HCT116 and MCF-7 cell lines. Nevertheless, similar 
to the above, compounds containing the di-2-pyridylketone 
moieties (3a, 3b and Dp44mT) and the 8-hydroxyquinoline 
derivative (2a) exhibited the highest Cu2+-dependent 
cytotoxicity against both cancer cell lines. On the other 
hand, after interacting with Cu2+, we observed the greatest 
improvement in cytotoxicity in the case of the 1c and 
2b compounds in HCT116 cells (more than a ten-fold 
increase) and for 1b, 3a, 3b (eight-fold) in MCF-7 cells. 
Reactive oxygen species formation – microscopic 
images 
To confirm the increased redox activity of the 
complexes with the tested compounds, we performed 
fluorescence imaging using CellROX, which binds to 
DNA upon oxidation and thus, its signal is localized 
primarily in the nucleus and mitochondria. The results are 
presented in Figure 2. 
Interacting with transition metal ions may increase 
the ROS level in the cytosol and cause cell death. This 
mechanism has also been suggested for TSC [21]. All 
of the thiosemicarbazones that were tested increased the 
level of ROS significantly and were similar to hydrogen 
peroxide, which was used as the positive control. 
Additionally, after treatment with the tested compounds, 
we observed a strong fluorescence signal, which may 
primarily be focused on the mitochondria and nucleus.
Time dependent measurement of ROS level
As presented in Figure 3, the ROS level gradually 
rose over the time and reached the highest level after 
twelve hours of incubation, after which it dropped rapidly. 
Although this pattern was observable in all of the tested 
compounds, it appeared to correlate well with the activity 
of the TSC. Compound 3a had the strongest effect, 
followed by Dp44mT and 2a. On the other hand, 1a-c 
and 3c caused only a minute increase in the ROS level. 
This may confirm that the main aspect of the multiway 
mechanism of the activity TSC relies on the Fenton and 
Haber-Weiss reactions. 
Scheme 1: General method for synthesis of studied TSC.
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Time dependent measurement of glutathione level
Previous results prompted us to study the influence 
of the tested TSC on the GSH level. We performed 
experiments in the same conditions (as for the ROS level), 
but this time the concentration of the natural antioxidant 
(GSH) was measured. Results are shown in Figure 4. 
A high level of ROS led to the oxidation of 
glutathione and diminished the overall antioxidative 
potential in a cell. Time-dependent changes in the GSH 
level confirmed the increased vulnerability of the cells 
to ROS-dependent damage. This in turn prompted us to 
evaluate the gene expression under the oxidative stress 
that was induced by the TSC. 
The antioxidative genes expression 
The antioxidative genes concentration levels are 
presented in Figure 5.
In general, most of the tested TSC caused a decrease 
in the expression of MnSOD (Figure 5) progressing with 
incubation time, except of 2a, where slight increase can 
be noticed. For compound 1a however, after the initial 
decline (for 12 h) there is a small increase in expression 
of MnSOD. In the case of catalase, the effect was strongly 
dependent on time as its level was higher for the active 
compounds (2b, 3a, 3b, 1c) after the first 12 h. Then, 
after the next 12 h, it decreased dramatically for all of the 
thiosemicarbazones that were tested. This downregulation 
of MnSOD and CAT could be explained by the 
interruption in the cellular oxidative equilibrium towards 
the induction of strong oxidative stress. The level of ROS 
is so high, that mechanisms responsible for protecting the 
cell collapsed. Therefore, leading to trigger the pathways 
involved in the cell death. One of the factors engaged in 
the apoptosis induction is Ndrg1 protein. As is shown 
in the Figure 5 the Ndrg1 gene level rose considerably 
after 24 h of incubation with the TSC. This effect was the 
Table 1: Antiproliferative activity of the studied compounds
Comp. R
Activity - IC50 [nM]
HCT116 HCT116+ Cu2+ HCT116+ Fe3+ MCF-7 MCF-7+ Cu2+ MCF-7+ Fe3+ NHDF
1a 87.70 ± 43.86a 59.57 ± 6.45 96.91 ± 16.92 219.00 ± 15.10 44.90 ± 3.77 273.40 ± 35.65 9.44·103 ± 3.84·103a
1b 62.21 ± 8.95 19.67 ± 0.53 72.37 ± 12.90 31.39 ± 3.38 3.78 ± 0.88 24.97 ± 2.16 114.40 ± 10.30
1c 72.14 ± 9.40 7.19 ± 1.84 70.81 ± 7.28 17.25 ± 2.71 4.48 ± 1.18 39.13 ± 6.51 17.07·103 ± 1.41·103
2a 3.84 ± 1.46a 1.39 ± 0.44 7.57 ± 1.19 10.87 ± 2.85 2.39 ± 0.42 8.83 ± 1.29 10.64·103 ± 3.48·103a
2b 50.50 ± 28.10a 4.17 ± 1.12 78.16 ± 14.00 32.23 ± 6.85 5.49 ± 1.19 35.83 ± 5.82 12.14·103 ± 3.58·103a
3a 0.81 ± 0.13a 0.68 ± 0.15 2.07 ± 0.78 11.98 ± 2.04 1.55 ± 0.55 8.96 ± 1.81 1.73 ± 0.71a
3b 2.06 ± 0.88a 1.56 ± 0.44 9.94 ± 2.69 4.10 ± 0.93 0.54 ± 0.15 5.35 ± 0.66 160.00 ± 40.00a
3c 37.80 ± 3.05a 4.95 ± 1.64 29.53 ± 3.69 25.60 ± 6.74 4.41 ± 1.50 16.58 ± 2.25 13.85 ± 0.03a
Dp44mT - 1.40 ± 0.13a 0.31 ± 0.06 1.77 ± 0.36 0.38 ± 0.15 0.13 ± 0.04 0.96 ± 0.32 15.38·103 ± 5.06·103a
DOX - 91.00 ± 6.96 62.50 ± 8.24 84.84 ± 11.22 404.90 ± 38.00 335.60 ± 65.35 413.60 ± 59.05 137.00 ± 26.00
adata from [35].
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strongest for 2b, 3b, and 3c. We also observed significant 
increase for 3a, but after 12 h. These results indicate that 
the cell entered on the apoptosis pathway [45].
Western blot analysis of the cell cycle and 
apoptosis proteins 
Antioxidant genes expression indicated that 
tested TSC influenced the ROS generation in cell. This 
prompted us to carry out further studies designed to reveal 
proteins responsible for cell cycle and death. As is shown 
on Figure 6 we explored p21, p53, and cdc2 proteins. 
We observed no influence on the p53 among all of the 
tested compounds, except DOX. Densitometric analysis 
of proteins indicated a marked up-regulation of p21 after 
incubation with 1c, 3c and Dp44mT (Figure 6B). For 
compounds 1b, and 3b we also noticed the increased 
p21 level, but in a lesser degree. In the case of cdc2 we 
detected a significant growth just for 3a. For the rest of 
the tested compounds we register down-regulation, which 
takes the lowest values for Dp44mT and 1b. 
Cell cycle assay 
We examined the effect of the tested TSC and DOX 
on the regulation of the cell cycle in HCT116 cells after 
48 h of incubation (Figure 7). Generally, we observed a 
significant decrease in the percentage of cells in the G0/
G1 phase after treatment with all of the tested compounds. 
Specifically, one of the most active compounds – 
3b diminished the cell count in the G0/G1 phase to 
39% compared to the untreated cells (72%) (Figure 
7B). Additionally, all of the TSC caused a significant 
increase of the fraction cells in the S phase of the cell 
cycle. In general, some differences after treatment with 
the compounds in series 1, 2 and 3 were observed. The 
compounds of 1a-c and 3b-c showed a significant increase 
in this proportion of cells of 40–48%. These results were 
comparable to those of Dp44mT (41%), while in the case 
of 2a, 2b and 3a, smaller effect was observed (33–35%). 
Thus, all of these data suggest that TSC may also induce 
cell death through the cell cycle arrest in the S and G2/M 
phases. For example, the compounds in series 2 and 
Figure 2: Formation of reactive oxygen species in HCT116 cells after 24 h treatment with the tested compounds 
(concentration 2 × IC50) and a 15-min incubation with hydrogen peroxide (100 µM), which was used as the positive 
control. The negative control consisted of untreated cells. Scale bars = 20 μm.
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Figure 3: Effect of the tested compounds (1 µM) and DOX (5 µM) on the level of ROS in HCT116 cells. Data normalized 
to untreated cells (control). Results are shown as the mean ± SD of three independent measurements. Data were analyzed using the 
Student's t-test: *p < 0.05, **p < 0.01, ***p < 0.001 compared to the control group.
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Figure 4: Effect of the tested compounds (1 µM) and DOX (5 µM) on the intracellular GSH content of HCT116 cells. 
Data normalized to the untreated cells (control). Results are shown as the mean ± SD of three independent measurements. Data were 
analyzed using the Student's t-test: *p < 0.05, **p < 0.01, ***p < 0.001 compared to the control group.
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compound 3a caused an increase in the cell count in the 
G2/M phase to 17% compared to the untreated cells (7%) 
(Figure 7B). 
Annexin V binding assay
The evaluation of apoptosis in the HCT116 cell 
line was confirmed using Annexin V staining. Results are 
presented in Figure 8.
As is presented in Figure 8, a significantly increased 
population of total apoptotic cells after treatment with 
tested the compounds can be observed. Moreover, the 
strongest effect was observed for 1c, 3c, Dp44mT and 
DOX, which correlates with their ability to significantly 
up-regulate the p21 protein. In the case of the 2a-b 
compounds, the lowest proportion of apoptotic cells was 
observed, which may be associated with a late entry into 
apoptosis or undergoing a mitotic catastrophe. In this 
case, a higher chelation ability and the disruption of the 
antioxidant potential of a cell may be connected with a 
stronger obstructive effect on cell cycle progression and a 
lower overall apoptotic cell count. 
Intercalation 
Further, we studied the ability of tested 
thiosemicarbazone derivatives to bind DNA strains. The 
absorption spectra of the tested compounds in the absence 
and presence of calf-thymus DNA, which is presented in 
Figure 9 and Table 2, summarize the absorption spectral 
properties of the tested thiosemicarbazones. Our results 
indicate that DNA intercalation is strongly possible in the 
tested TSC, which results in a decrease in band intensities 
and a small shift of the wavelength. These changes in the 
band intensities of the spectra (hypochromism) are caused 
by the contraction of the DNA helix axes and also from the 
conformational changes on the molecules of DNA [46]. 
TSC (3a-c) with a fragment of dipyridyl ketone revealed 
the strongest hypochromism of about 28.2%, 31.9% 
and 28.5%, respectively. These values are similar to the 
reference – doxorubicin, which is a well-characterized 
DNA-intercalation drug [47]. In our experiments, we 
observed a significant decrease in the absorption intensity 
of about 34.2% for doxorubicin. Interestingly, Dp44mT 
showed a very weak ability to intercalate DNA, which has 
also been confirmed by other groups [23, 48]. However, 
thiosemicarbazones 1a-c, which are based on the quinoline 
moiety, showed good intercalation properties and strong 
hypochromism of about 22.0%, 24.2% and 22.6%, 
respectively, was observed. 
DISCUSSION
Dipyridyl- and quinolinyl-based TSC are among 
the most potent antiproliferative compounds of this class 
[23]. Among them, we recently identified a series of 
derivatives that appeared to be thousands of times more 
effective than Triapine against several human cancer cell 
Figure 5: mRNA expression of MnSOD, CAT and Ndrg1 in the HCT116 cell line after incubation with TSC (1 µM) and 
doxorubicin (5 µM). Results are shown as the mean ± SD of three independent measurements, each in triplicate. Data were analyzed 
using the Student's t-test: *p < 0.05, **p < 0.01, ***p < 0.001 compared to the control (untreated cells).
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lines [35]. In this paper we present several compounds, 
which possess strong anticancer activity (1a, 2b, 3a, 
3b), and a promising selectivity index. Antiproliferative 
activity of these compounds was investigated along with 
apparent mechanism of action. In general TSC can be 
regarded as metal chelators. According to the hypothesis 
presented by Ding and Lind metal chelating compound 
can be classified as chelator, metal shuttle or ionophore 
regarding to the intrinsic mechanism of action [50]. This 
can be distinguished by testing the activity changes in 
metal overload or complexes. For TSC however series 
of complexes were synthesized and tested providing 
ambiguous results [51]. Both the increase [21] and 
decrease [23] of activity have been reported for various 
complexes. For active compounds, that are tested 
in much smaller concentrations than metal ions, the 
ionophoric mode (ligand transports multiple ions through 
membranes) seems to be predisposed [40, 52, 53]. To test 
the ionophore hypothesis, we studied the influence of 
metal ions on the cytotoxicity of the TSC. Human colon 
cells and breast cancers are particularly suitable for this 
study because of their higher sensitivity to an increased 
ROS level due to their higher basal level [54]. Both of 
the cell lines (HCT116 and MCF-7) used in this study 
are also known for their the relatively high level of iron 
and iron-regulatory proteins [55–57]. Moreover, drugs 
that impair the level of cellular iron were found to be less 
vulnerable to resistance in these cells [58, 59]. All of the 
TSC that were tested are potent iron chelators that are 
able to change the iron concentration within a cell [34, 
35]. The overall cytotoxic effect, however, depends on 
the cells susceptibility to changes in the iron and ROS 
levels. Similar differences have been described for the 
leukemia [60], neuroepithelioma [23] and neuroblastoma 
[61] cell lines. In the case of copper ions we observed 
even higher increase of the activity. One explanation 
for these observations may be the different chelating 
ability of tested TSC, as we suggested in the case of iron. 
Moreover cancer cells are more sensitive for the change 
of the Cu2+ level as basal level of this metal is elevated, 
particularly in prostate and breast cancers [62]. Copper 
chelators with ionophoric activity are known for their 
promising potency and selectivity towards cancer cells. 
An example of such compounds studied in clinical trials 
is clioquinol or bisthiosemicarbazone [16]. However the 
exact mechanism of their activity is not clarified, they tend 
Figure 6: Influence of the tested compounds (1 µM) and DOX (5 µM) on the expression of cdc2, p21, p53 and β-actin in HCT116 cells 
(A). Data for p21 and cdc2 were analyzed using one-way ANOVA with Bonferroni’s post-hoc test: *p < 0.05, **p < 0.01, ***p < 0.001 
compared to the control (B).
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Figure 7: Impact of TSC (1 µM) and DOX (5 µM) treatment on the regulation of the cell cycle in HCT116 cells. The 
histograms show the distribution of cells in the G0/G1, S and G2/M phases of the cell cycle for one of the experiments (A). The table shows 
the mean ± SD percentage of cells in the G0/G1, S and G2/M phases of the cell cycle from three independent experiments (B). Data were 
analyzed using one-way ANOVA with Bonferroni’s post-hoc test: *p < 0.05, **p < 0.01, ***p < 0.001 compared to the control (C).
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Figure 8: Evaluation of apoptosis induction in HCT116 cells after 48 h of treatment with TSC (1 µM) and DOX (5 µM). 
The histograms show the percentage of early and late apoptosis for one of experiments (A). The table shows the mean ± SD percentage of 
live, early and late apoptotic cells from three independent experiments (B). Data were analyzed using one-way ANOVA with Bonferroni’s 
post-hoc test: *p < 0.05, **p < 0.01, ***p < 0.001 compared to the control (C).
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to increase oxidative processes or displacing other metals 
from their complexes with specific proteins. The redox-
active complexes of Dp44mT with lysosomes specific 
accumulation were reported by Lovejoy et al. [40]. Both 
of the structural fragments (quinoline/di-pyridine and 
thiosemicarbazone moieties) that are exploited in those 
new TSC are known to chelate metal ions. Considering 
this, we decided to investigate the mechanisms of 
oxidative stress induction after treatment with those highly 
potent TSC more deeply. 
Our recent studies confirmed that TSC derivatives 
may be accumulated also in mitochondria [37]. This 
suggests that the ROS that were generated by the TSC may 
influence the antioxidant capacity and contribute to the 
disruption of mitochondria, which then triggers apoptosis. 
To evaluate this hypothesis, we measured the intracellular 
level of ROS and glutathione in time dependence manner. 
Results shown reverse dependence of changing ROS 
and GSH level. In general, ROS concentration increased 
along incubation time, reaching the maximum after 12 h. 
The opposite effect was observed for GSH. Its level 
decreased during the whole experiment lasting 24 h. GSH 
depletion is a strategy to overcome MDR-resistance and it 
is also an early event in cell death in response to different 
stimuli [12]. This, however, may occur in two different 
ways depending on the contribution of p53 [63, 64]. 
Figure 9: Absorption spectra of the tested thiosemicarbazones and DOX in the absence of CT-DNA (solid line) and in 
the presence of the CT-DNA (dotted line) in phosphate-buffered saline. Red line indicates the CT-DNA alone in PBS.
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For 3a we detected the highest ROS level (12 h), among 
all of the tested compounds. This can be correlated 
with anticancer activity and confirmed hypothesis, that 
mechanism of action is connected with ROS generation. 
Therefore the next step was to measure the expression 
of genes responsible for maintaining oxidative balance 
in cell. Genes expression dynamic correlates with the 
antiproliferative activity of the tested compounds. Such 
a reduction in antioxidant proteins following ROS-
induced damage is a known trigger of apoptosis [65]. 
The inhibition of manganese superoxide dismutase and 
catalase expression appears to play a crucial role in 
breaking down the cellular defense against increased ROS 
level. Additionally catalase may affect the mechanism 
of multidrug resistance and protect tumor cells against 
the induction of apoptosis [66, 67]. Ndrg1 expression is 
another important factor in the stress response that was 
observed to be considerably elevated. This gene is down-
regulated in various cancers, which is often connected with 
p53 level [68]. Amplification of this gene is frequently 
reported in response to chemotherapy and leads to the 
inhibition of growth and metastasis. Alterations of the 
intracellular level of iron through chelation and facilitated 
mobility have been identified as one of the triggers of 
Ndrg1 up-regulation [22]. 
With this in mind, we determined the influence 
of the tested TSC on the expression of p53 and p21 
proteins, which are involved in cell cycle progression 
and apoptosis induction. Interestingly, none of the tested 
TSC induced the expression of the p53 protein. On the 
other hand, western blot analysis revealed a considerable 
up-regulation of the p21 protein after treatment with all 
of the compounds that were tested. The strongest effect, 
comparable to DOX, among the TSC was observed for 1c, 
3c and Dp44mT. Those results indicate a p53-independent 
pathway of apoptosis. The Ndrg1 gene has also been 
reported to up-regulate p21 and activate WAF1/CIP1 
expression as apoptotic triggers [69–71]. 
Cellular ROS level is strictly related to the cell 
cycle. In general a concentration of oxygen radical is 
steadily growing from G1 through S phase to G2 + M 
and then drops back in quiescent state. Both antioxidant 
factors and prooxidant proteins are respectively changing, 
regulated by overall metabolism rate [72, 73]. For example 
MnSOD level is repeatedly changing from high in G1 and 
S phases to low in G2/M. The same was observed for its 
conformation and electrostatic potential [74]. To fulfill the 
increased demand for energy, cells in the G0/G1 phase 
increase the activity of proteins such as MnSOD, which 
are responsible for redox homeostasis. As was suggested 
by Sarsour et al., eustress and oxidative stress are both 
crucial factors in cell cycle progression [72]. In response 
to oxidative damage or radiation stress MnSOD may be 
regulated through phosphorylation by cdc2 [75, 76]. 
Interestingly compounds 1b, 3b and 3c with strongest 
decreasing effect on cdc2 (Figure 6) caused also a large 
drop in the MnSOD level after 24 h of incubation (Figure 5). 
On the other hand however 2b and 3a increased the 
expression of cdc2. The cdc2 protein is involved in 
the transition from the G2 to M phase and its activity is 
sustained from the prophase to the metaphase during 
mitosis. Moreover, for 2b and 3a a relatively smaller 
increase in S phase and the highest increase in G2/M may 
be observed. Therefore, our results confirm cell cycle 
arrest in the S or G2 phase and the initiation of a mitotic 
catastrophe in HCT116 cells [77, 78]. On the other hand, 
Topham et al. postulated that the prolonged arrest of cells 
in the mitotic phase leads to their death via apoptosis, 
which is associated with the mitochondria signaling 
pathway [79].
Another possible mechanism of action, which 
characterizes most planar aromatic compounds, is 
Table 2: Absorption spectral properties of the tested compounds bound to CT-DNA
Compound Absorption λmax [nm]
Changes in 
absorbance % hypochromism Δε M
−1 cm−1 blue/red shift* [nm]
1a 282; 334 hypochromism 22.0 3175.6 1
1b 324 hypochromism 24.2 2313.3 10
1c 272; 310 hypochromism 22.6 2695.6 4
2a 295; 330 hypochromism 15.7 1935.6 10
2b 295; 338 hypochromism 9.4 1888.9 5
3a 325 hypochromism 28.2 4120.0 5
3b 320 hypochromism 31.9 6133.3 5
3c 330 hypochromism 28.5 3220.0 2
Dp44mT 272; 324 hypochromism 8.2 1673.3 2
DOXa 480 hypochromism 34.2 3235.6 10
*for the wavelengths of the maximum absorption for compounds alone and the DNA-bound compounds. adata from [49].
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intercalation of DNA. This can also be associated with 
interactions with transition metals such as iron, copper 
and nickel, which can form complexes with quinolines, 
8-hydroxyquinolines and thiosemicarbazone derivatives 
[80–83]. Additionally, in previous studies, we indicated 
that the antiproliferative activity of quinoline-related 
compounds may be associated with the ability to intercalate 
into DNA, leading to the p53-independent mechanism 
of action of these compounds [49, 84]. Moreover, many 
iron chelators have been reported to be topoisomerase 
inhibitors or poisons [85]. The ability of ligands or metal 
complexes to bind to DNA may induce conformation 
changes, which as a result leads to DNA strand stress 
and damage [86]. In general interactions ligand-DNA 
may induce hypo- or hyperchromism. First is attributed 
with interaction of electronic state of compounds and 
those of DNA bases, increasing tightness of complex and 
π-stacking. The second effect, may reflect electrostatic 
binding (groove binders) or partial uncoiling of helix, as 
single stranded DNA revealed much stronger absorption 
as double helix. Strong hypochromism combined with red- 
or blue-shift is regarded as typical sign of intercalation. 
The stronger the effect and wavelength shift associated, 
the stronger interaction is. Our results shown in general 
high intercalating potency of TSC that were tested. An 
exception is control compound Dp44mT, for which 
only small effect was observed. This simple, dimethyl-
substituted molecule is known for weak interactions with 
CT-DNA [48]. Thus our results indicate the importance 
of both of the substructures that are connected with the 
thiosemicarbazone moiety. Di-pyridine or quinoline 
rings and large aromatic rings instead of dimethylamine 
(compare 3a-c and Dp44mT), particularly the piperazine 
ring, may interact with minor groove DNA and thereby 
improve intercalation [87]. For this series of TSC strongest 
hypochromism and strong red- or blue-shift was observed. 
For substituted pyridine 3b the strongest hypopchromic 
effect was observed comparable with this of doxorubicin. 
On the other hand, series 2 of the thiosemicarbazones with 
the 8-hydroxyquinoline moiety had moderate intercalating 
properties. The combination of DNA intercalation and 
redox-active complexes may be responsible for the small 
amount of damage in the structure of the nucleic acids, 
which leads to cell cycle arrest as was indicated above. 
This hypothesis may explain the conflicting literature data 
suggesting that TSC do [88] or do not [89] interact directly 
with topoisomerases. This also corresponds with the fact 
that even non-intercalating TSC may induce some DNA 
damage via Cu-complexes [90].
To sum up the ionophoric nature of these chelators 
and a high activity in the Haber-Weiss and Fenton reactions 
are responsible for their complex interactions with the 
cellular antioxidant system. The aromatic structure and 
chelation ability of novel TSC is a prerequisite for DNA 
intercalation. Increasing the ROS levels beyond the 
restoration capacity of a cell affects the regulation of the 
MnSOD and CAT genes. This in turn up-regulates the 
Ndrg1 gene and leads to apoptosis. Despite the strong 
connection between iron metabolism and p53, all of the 
tested compounds triggered cell death in a p53-independent 
manner. These findings will hopefully help to understand 
and clarify the reports that are often contradictory.
MATERIALS AND METHODS
Synthesis
General reagents were purchased from Sigma-Aldrich 
(St. Louis, MO, USA) or ACROS Organics (Belgium). 
Thin layer chromatography (TLC) was performed on 
alumina-backed silica gel 40 F254 plates (Merck) and 
illuminated under UV (254 nm) The melting points were 
determined on Optimelt MPA100 instrument (SRS, USA) 
and are uncorrected. Syntheses were performed on a CEM-
DISCOVERY microwave reactor (CEM Corporation, 
Matthews, NC, USA) with temperature and pressure 
control. High resolution mass spectrometry (HRMS) 
analysis was performed for all new compounds on SYNAPT 
G2-S HDMS (Waters, USA). The purity of all compounds 
was assessed using a Agilent1260 equipped with a DAAD 
detector at 260 nm, RP-column: Eclipse plus C18 (3,5 μm); 
flow 0.5 ml/min. The time of each measurement was 21 
min. Conditions: 0− 0.8 min (80% H2O (0.1% TFA); 20% 
acetonitrile); 0.8−7 min (100% acetonitrile); 7−13 min (80% 
H2O (0.1% TFA); 20% acetonitrile).
All 1H NMR spectra were recorded on a Bruker 
AM-400 spectrometer (400 MHz) as well as Bruker 
AVANCE III (500 MHz). Chemical shifts are reported 
in ppm against the internal standard, Si(CH3)4. Easily 
exchangeable signals were omitted when diffuse. In 
general, thiosemicarbazones – 1a, 2a-b, 3a-c, Dp44mT 
and their thiosemicarbazide precursors were synthesized 
and characterized, as described previously [35, 36]. 
Doxorubicin was purchased from Sigma-Aldrich.
General procedure for the synthesis of 
thiosemicarbazones 1b-1c
The mixtures of (1,1′-thiocarbonyl) bis-1H-
imidazole (5 mmol) and 4-(4-fluorophenyl)piperazine 
(5 mmol) or 4-[3-chloro-5-(trifluoromethyl)pyridin-
2-yl]piperazine (5 mmol) in methylene chloride (25 
mL) were stirred for 24 h at room temperature. The 
solutions were extracted three times with distilled water 
and the organic phases were dried over MgSO4 and 
evaporated. The obtained thioketones were refluxed for 
2 hours with hydrazine hydrate (5 mmol). Finally, crude 
thiosemicarbazides were crystallized from dry methanol to 
obtain pure crystals. NMR spectra and mass spectrometry 
analysis is provided in Supplementary Figures 1–8.
4-(4-fluorophenyl)piperazine-1-carbothiohydrazide 
Light pink powder; yield 97%; mp:180–181° C; 1H-NMR 
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(400 MHz, d6-DMSO, ppm): δ 3.09 (m, 4H, CH2), 3.87 
(m, 4H, CH2), 4.77 (s, 2H, NH2), 6.97 (m, 2H, CH), 7.05 
(m, 2H, CH), 9.19 (s, 1H, NH). 13C-NMR (101 MHz, d6-
DMSO, ppm): δ 40.3; 49.1; 115.9; 117.9; 148.0; 157.8; 
183.0.
4-[3-chloro-5-(trifluoromethyl)pyridin-2-yl]
piperazine-1-carbothiohydrazide White powder; yield 
85%; mp:191–192° C; 1H-NMR (500 MHz, d6-DMSO, 
ppm): δ 3.51 (m, 4H, CH2), 3.88 (m, 4H, CH2), 4.83 (s, 
2H, NH2), 8.20 (d, 1H; J = 2.1 Hz), 8.56 (s, 1H, CH), 
9.18 (s, 1H, NH). 13C-NMR (126 MHz, d6-DMSO, ppm):
 
δ 47.3; 48.1; 120.2; 122.8; 125.0; 136.8; 143.5; 159.7; 
183.2.
Microwave-assisted synthesis of thiosemicarbazones
Two drops of glacial acetic acid were added as a 
catalyst to the mixtures of thiosemicarbazides (0.5 mmol) 
and appropriate quinolinecarboxaldehyde (0.5 mmol) in 
ethanol (5 mL). The glass tubes were sealed and placed 
into a microwave reactor at 83º C for 20 minutes (the 
reactor power did not exceed 50 W). The final products 
were crystallized from methanol. 
4-(4-fluorophenyl)-N’-[(quinolin-2-yl)methylidene]
piperazine-1-carbothiohydrazide (1b) Yellow powder; 
yield 62%; mp:192–193° C; 1H-NMR (500 MHz, d6-
DMSO, ppm): δ 3.26 (m, 4H, CH2); 4.13 (m, 4H, CH2); 
7.02 (m, 2H, Ar-H); 7.09 (t, 2H, J = 8.9 Hz); 7.63 (m, 
1H, Ar-H); 7.78 (m, 1H, Ar-H); 7.99 (m, 1H, Ar-H); 8.03 
(m, 2H, Ar-H); 8.35 (s, 1H, CH); 8.39 (d, 1H, J = 8.7 
Hz); 11.67 (s, 1H, NH). 13C-NMR (126 MHz, d6-DMSO, 
ppm): δ 49.4; 50.4; 115.8; 115.9; 117.8; 127.6; 128.2; 
128.5; 129.3; 130.5; 137.2; 144.4; 147.9; 154.3; 155.8; 




(1c) Yellow powder; yield 98%; mp:126–127° C; 1H-NMR 
(500 MHz, d6-DMSO, ppm): δ 3.69 (m, 4H, CH2); 4.14 
(m, 4H, CH2); 7.62 (m, 1H, Ar-H); 7.79 (m, 1H, Ar-H); 
8.01 (m, 3H, Ar-H); 8.23 (d, 1H, J = 2.2 Hz); 8.34 (s, 1H, 
CH); 8.38 (d, 1H, J = 8.7 Hz); 8.59 (dd,1H, J = 2.1, 0.9 
Hz); 11.68 (s, 1H, NH). 13C-NMR (126 MHz, d6-DMSO, 
ppm): δ 19.0; 48.3; 50.2; 56.5; 117.8; 120.0; 127.6; 128.2; 
128.5; 129.3; 130.5; 136.9; 137.1; 143.5; 144.4; 147.9; 
154.3; 159.6; 181.6. HRMS-ESI: calcd for C22H19ClF3N5S 
479.1033 [M+H]+ found 479.1025.
Cell culture
The human colon cancer cell line HCT116 wild 
type and human breast carcinoma cell line MCF-7 were 
obtained from ATCC and the normal human fibroblast cell 
lines NHDF were obtained from PromoCell. Cells were 
grown as monolayer cultures in Dulbecco’s modified 
Eagle’s medium with an antibiotic gentamicin (200 
μL/100 mL medium) in 75 cm2 flasks (Nunc). DMEM for 
HCT116 and MCF-7 were supplemented with 12% heat-
inactivated fetal bovine serum (Sigma) and for NHDF 
with 15% non-inactivated fetal bovine serum (Sigma). 
Cells were cultured under standard conditions at 37° C in 
a humidified atmosphere at 5% CO2.
Cytotoxicity studies
The cells were seeded in 96-well plates (Nunc) at 
a density of 3,500 cells/well (HCT116 and MCF-7) and 
3,000 cells/well (NHDF) and incubated at 37° C for 24 h. 
The assay was performed following a 96 h incubation with 
varying concentrations of the compounds that were being 
tested. Then, 20 µL of CellTiter 96® AQueous One Solution-
MTS (Promega) was added to each well (with 100 µL 
DMEM without phenol red) and incubated for 1 h at 37° 
C. The optical densities of the samples were analyzed at 
490 nm using a multi-plate reader (Synergy 4, Bio Tek). 
Results were expressed as a percentage of the control 
and calculated as the inhibitory concentration (IC50) 
values (using GraphPad Prism 5). The IC50 parameter 
was defined as the compound concentration that was 
necessary to reduce the proliferation of cells to 50% of the 
untreated control. Each individual compound was tested 
in triplicate in a single experiment with each experiment 
being repeated three or four times.
Impact of metal ions on cellular proliferation
The HCT116 and MCF-7 cells were seeded in 
96-well plates (Nunc) at a density of 3,500 cells/well 
and incubated at 37° C for 24 h. The MTS assay was 
performed following a 96 h incubation with varying 
concentrations of the tested compounds. Additionally, 
a 20 µM solution of CuSO4, FeSO4 or FeCl3 was added 
into wells with the tested compounds. The results were 
expressed as a percentage of the control and calculated as 
the inhibitory concentration (IC50) values using GraphPad 
Prism 5. Each individual compound was tested in triplicate 
in a single experiment with each experiment being 
repeated three times.
Reactive oxygen species formation – microscope 
images 
The HCT116 cells were seeded into eight-well 
chambers (Lab-Tek) at a density of 0.5 × 105 cells/well and 
incubated at 37° C. After 24 h, freshly prepared solutions 
of the tested compounds: 1b, 1c, 2a-b, 3a-c and DOX (two-
fold IC50 concentration) were added. The next day, the 
solutions of the tested compounds were removed and the 
cells were washed with Phosphate Buffered Saline (PBS), 
after which 5 μM CellROX® Green Reagent (Molecular 
Probes™) was added. After 30 min of incubation at 37° C, 
the cells were washed with PBS and then DMEM without 
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phenol red was added. The observation was performed 
using an inverted fluorescence microscope (IX81, 
Olympus) equipped with a CO2 incubator using a 485 nm 
excitation laser and a 520 nm emission filter.
Time dependent measurement of ROS level
To determine the intracellular levels of ROS, 
HCT116 cells were seeded onto black 96-well plates 
(Corning) at a density of 9,000 cells/well and incubated at 
37° C. After an overnight incubation, the solutions of the 
tested compounds: 1a-c, 2 a-b, 3 a-c, Dp44mT (1 μM) and 
DOX (5 μM) were added and incubated for 3, 6, 9, 12, and 
24 h in a kinetic experiment. The generation of ROS was 
measured using a CellROX® Green Reagent (Molecular 
Probes™). Additionally, the quantity of cells in each 
well was determined using Hoechst 33342 (Molecular 
Probes™). The solutions of the tested compounds were 
removed and 100 µL of CellROX Green Reagent and 
Hoechst 33342 at a final concentration of 5 μM were 
added to each well. Then, the cells were incubated for 
30 min at 37° C. The fluorescence was measured using 
a multi-plate reader (Synergy 4, Bio Tek) at 485 nm 
excitation and a 520 nm emission for CellROX Green 
Reagent and a 345 nm excitation laser and a 485 nm 
emission filter for Hoechst 33342. The experiments were 
performed three to four times. ROS levels were expressed 
as the percentage of the control cells level.
Time dependent measurement of glutathione 
level
To determine the intracellular level of reduced 
glutathione, the HCT116 cells were seeded in 3 cm Petri 
dishes (Nunc) at a density of 0.5 × 106 cells/well and 
incubated at 37° C. The next day, solutions of TSC (1 μM) 
and DOX (5 μM) were added and incubated for 3, 6, 9, 12, 
and 24 h in a kinetic experiment. The levels of intracellular 
GSH were measured using an enzymatic recycling method 
[91]. Briefly, 20 μL of each cell lysate was transferred 
into 96-well plates. Then, freshly prepared solutions of 
5,5′-dithio-bis(2-nitrobenzoic acid) (DNTB) at a final 
concentration of 0.67 mg/mL and glutathione reductase 
(GR) – 1.67 units/mL, were added to each well. After 30 
sec, β-NADPH (0.67 mg/mL) was added to each well and 
the absorbance was immediately measured at 412 nm in a 
multi-plate reader (Synergy 4, Bio Tek). The experiments 
were performed in triplicate. Data were expressed as the 
percentage of the control cells level.
Analysis of the mRNA expression of MnSOD, 
CAT, Ndrg1
The HCT116 cells were seeded in 3 cm Petri dishes 
(Nunc) at a density of 0.5·106 cells/well and incubated 
overnight. Next, the medium was removed and solutions 
of TSC (1 μM) and DOX (5 μM) were added. After 12 or 
24 h, total RNA was isolated from the cells using TRIzol 
Reagent (Ambion) according to the manufacturer’s 
instructions. cDNA synthesis was performed with 5 μg 
of total RNA using a GoScript™ Reverse Transcriptase 
kit (Promega) and Oligo(dT)23 Primers (Sigma). The 
Real-Time PCR was performed with a CTX96 Touch™ 
Real-Time PCR Detection System (Biorad) in a 20 μL 
reaction volume. The reaction consisted of PowerUp™ 
SYBR® Green Master Mix (Applied Biosystems), a 
primer pair mix (0.5 μM each) and 1 μL of cDNA. All 
primer pair sequences were purchased from Sigma-
Aldrich and are listed in Supplementary Table 2. The 
experiment was performed under the following conditions: 
initial denaturation at 95° C for 120 sec; followed by 40 
denaturation cycles at 95° C, 15 sec; annealing (primer-
specific temperature for 30 sec) and extension at 72° C 
for 60 sec. Data was analyzed based on a comparison of 
the expression of the target genes to a reference gene – 
β-actin, using the 2–ΔΔCT method. The experiments were 
performed at least three times.
Immunoblotting
The HCT116 cells were seeded in 3 cm Petri dishes 
(Nunc) at a density of 0.5·106 cells/well and incubated 
overnight. The next day, solutions of TSC (1 μM) and 
DOX (5 μM) were added and the cells incubated for 24 or 
48 h. Cells were harvested by trypsinization and washed 
with cold PBS. Next, the cells were centrifuged and 
suspended in an RIPA buffer (Thermo Scientific) containing 
Halt Protease Inhibitor Cocktail (Thermo Scientific), Halt 
Phosphatase Inhibitor Cocktail (Thermo Scientific) along 
with 0.5 M EDTA and lysed for 20 min on ice. Then, the 
lysates were sonicated, centrifuged at 10,000 rpm for 10 
min at 4° C and the supernatants were collected for further 
analysis. The protein concentration was determined using 
a Micro BCA™ Protein Assay Kit (Thermo Scientific) 
according to the manufacturer’s instructions. Equal 
amounts of the proteins (20 μg) were electrophoresed 
on SDS-Page gels and transferred onto a nitrocellulose 
membranes. The membranes were blocked in 5% non-fat 
milk prepared in PBS containing 0.1% Tween-20 (TPBS) 
for 1 h. After blocking, the membranes were incubated with 
specific primary antibodies: cdc2 (#POH1, Cell Signaling), 
p21Waf1/Cip1 (#12D1, Cell Signaling), p53 (#1C12, Cell 
Signaling) and β-Actin (#8H10D10, Cell Signaling) 
overnight at 4° C, then washed and incubated with 
horseradish peroxidase (HRP)-conjugated secondary 
antibodies for 1h at room temperature. All of antibodies 
were diluted 1:1000 in 5% milk in TPBS. Finally, the 
membranes were washed and incubated with a SuperSignal™ 
West Pico Chemiluminescent Substrate (Thermo Scientific). 
The chemiluminescence signals were captured using a 
ChemiDoc™  XRS+ System (BioRad). The experiments 
were performed at least three times. Densitometric analysis 
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was performed using ImageJ 1.41 software (Wayne 
Rasband, National Institutes of Health, USA).
Cell cycle assay
The HCT116 cells were seeded in 3 cm Petri dishes 
(Nunc) at a density of 0.25·106 cells/well and incubated 
at 37° C for 24 h. Then, the medium was removed and 
freshly prepared solutions of the tested TSC (0.5 μM) 
and DOX (5 μM) were added. After a 48 h treatment, 
assays were performed using a Muse Cell-Cycle Kit 
(Millipore) according to the manufacturer’s instructions. 
Briefly, cells were collected, washed with cold PBS and 
centrifuged at 300 g. Then, the cells were fixed in ice cold 
70% ethanol and stored at –20° C overnight. Afterwards, 
the cells were centrifuged and resuspended in 200 μL of 
Muse™  Cell Cycle Reagent and incubated for 30 min at 
room temperature in the dark. After staining, the cells 
were processed for cell cycle analysis using a Muse Cell 
Analyzer (Millipore). The experiments were performed at 
least three times.
Annexin V binding assay
The HCT116 cells were seeded in 3 cm Petri dishes 
(Nunc) at a density of 0.25·106 cells/well and incubated at 
37° C for 24 h. Then, the medium was removed and freshly 
prepared solutions of the tested TSC (0.5 μM) and DOX 
(5 μM) were added. After 48 h, assays were performed 
using an Annexin V & Dead Cell Kit (Millipore) according 
to the manufacturer’s instructions. Briefly, detached and 
adherent cells were collected and centrifuged at 500 g for 
5 min. Afterwards, the resuspended cells were incubated 
with 100 μL of Muse™ Annexin V & Dead Cell Reagent 
for 20 min at room temperature in the dark. After staining, 
the events for live, early and late apoptotic cells were 
counted using a Muse Cell Analyzer (Millipore). The 
experiments were performed at least three times.
Intercalation
For the DNA binding studies, Calf-thymus DNA (CT-
DNA) was purchased from Sigma Aldrich. The lyophilized 
CT-DNA was dissolved in 10 mM Tris-HCl, pH 7.9, mixed 
gently and left overnight at 4° C. The purity of the CT-
DNA solution was determined by measuring the ratio of 
UV absorbance at 260 and 280 nm. A ratio more than 1.8 
indicated that the DNA was sufficiently free from proteins. 
Then, the concentration of CT-DNA was determined from 
the absorbance at 260 nm using an extinction coefficient of 
6600 M–1cm–1. The tested TSC and DOX were dissolved 
in DMSO to a concentration of 8.35 mM, which was 
then used as the stock solution for preparing the various 
concentrations (25, 12.5, 6 and 3 µM) in 1 mL in 10 mM of 
Tris-HCl (pH 7.9). Afterwards, 18 µM CT-DNA was added 
to the prepared solutions, which were incubated for 1.5 h 
at 37° C with occasional vortexing. The absorption spectra 
were measured using a Hitachi U-2900 spectrophotometer 
in range of 200–500 nm. All absorption spectra were 
imported and compared in OriginPro 8.0.
Statistical analysis
Results are expressed as the mean ± standard 
deviation (SD) from at least three independent 
experiments. Statistical analysis in the ROS, GSH 
measurements and expression of genes were performed 
using the two-tailed Student’s t-test. Statistical differences 
in the expression of proteins, progression of cell cycle and 
Annexin V binding assay were calculated using one-way 
ANOVA with a Bonferroni post-hoc test. A p-value of 
0.05 or less was considered to be statistically significant. 
GraphPad Prism v.5.0 software (GraphPad Software, 
USA) was used for analysis. 
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